Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "virus"

478 News Found

Govt revises NLEM and slashes prices of 39 drugs
Policy | September 04, 2021

Govt revises NLEM and slashes prices of 39 drugs

At present 18 per cent of the local pharmaceutical market is under government's price control


Covid-19 vaccine clinical trial for people with autoimmune disease
Drug Approval | September 03, 2021

Covid-19 vaccine clinical trial for people with autoimmune disease

Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study


Phase 2 of Covaxin intranasal trials begin in Kanpur
Biotech | September 02, 2021

Phase 2 of Covaxin intranasal trials begin in Kanpur

The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract


Granules India receive DRDO licence to manufacture and market 2-DG
News | September 02, 2021

Granules India receive DRDO licence to manufacture and market 2-DG

The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19


Indian National Institute validates Livinguard’s face mask
Drug Approval | August 28, 2021

Indian National Institute validates Livinguard’s face mask

Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).


Merck donates Rs 1.7 crore to IIT Bombay for Covid-19 research
News | August 26, 2021

Merck donates Rs 1.7 crore to IIT Bombay for Covid-19 research

The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology


RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant
Drug Approval | August 26, 2021

RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant

Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease


New data demonstrates efficacy of Viraleze anti-nasal spray for Covid-19
Biotech | August 24, 2021

New data demonstrates efficacy of Viraleze anti-nasal spray for Covid-19

Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets


AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF
Biotech | August 20, 2021

AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF

Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases


Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
Biotech | August 20, 2021

Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine

This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC